G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future

Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer es...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Gamero, Angel Mauricio, Pezuk, Julia Alejandra, Brassesco, María Sol, Tone, Luiz Gonzaga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372908/
https://www.ncbi.nlm.nih.gov/pubmed/30766748
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372908/
https://www.ncbi.nlm.nih.gov/pubmed/30766748
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030

Ejemplares similares